Strides Pharma Science Ltd Shows Technical Momentum Shift Amid Mixed Indicator Signals

Technical Trend Shift and Price Movement

Strides Pharma Science Ltd (NSE: 688428) closed at ₹1,044.00 on 28 Jul 2026, marking a 2.45% increase from the previous close of ₹1,019.00. The stock traded within a range of ₹1,022.30 to ₹1,050.70 during the day, inching closer to its 52-week high of ₹1,231.45, while comfortably above its 52-week low of ₹769.60. This recent uptick aligns with a technical trend change from sideways to mildly bullish, signalling a potential shift in investor sentiment.

Moving Averages and Momentum Indicators

On the daily chart, moving averages have turned mildly bullish, indicating that short-term price momentum is gaining strength. This is a positive sign for traders looking for upward momentum in the near term. However, the weekly and monthly technical indicators present a more nuanced picture.

The Moving Average Convergence Divergence (MACD) indicator shows a mildly bearish signal on the weekly timeframe, suggesting some short-term caution. Conversely, the monthly MACD remains bullish, implying that the longer-term momentum is still positive. This divergence between weekly and monthly MACD readings highlights a transitional phase where short-term volatility may persist, but the broader trend retains an upward bias.

Relative Strength Index (RSI) and Bollinger Bands Analysis

The RSI on the weekly chart currently offers no clear signal, hovering in a neutral zone that neither indicates overbought nor oversold conditions. Meanwhile, the monthly RSI is bearish, signalling that the stock may be experiencing some selling pressure over the longer term. This mixed RSI outlook suggests that while short-term momentum is improving, investors should remain vigilant for potential pullbacks.

Bollinger Bands add further complexity to the technical landscape. On a weekly basis, the bands are mildly bearish, reflecting some contraction and potential volatility. However, the monthly Bollinger Bands are mildly bullish, indicating that the stock price is maintaining strength within its longer-term volatility range. This contrast reinforces the idea of a stock in transition, with short-term fluctuations but a generally positive long-term outlook.

Other Technical Indicators and Volume Trends

The Know Sure Thing (KST) oscillator, a momentum indicator, is mildly bearish on both weekly and monthly charts, suggesting some underlying weakness in momentum despite recent gains. The Dow Theory analysis shows no clear trend on either timeframe, indicating that the stock has yet to establish a definitive directional movement in the broader market context.

On-balance volume (OBV) analysis reveals no trend on the weekly chart and a mildly bearish trend on the monthly chart. This suggests that volume flows have not strongly supported the recent price gains, which could be a cautionary sign for investors relying on volume confirmation for trend strength.

Comparative Returns and Market Context

Strides Pharma’s recent returns have outperformed the broader Sensex index significantly over multiple time horizons. Year-to-date, the stock has delivered a robust 15.7% gain compared to the Sensex’s decline of 9.8%. Over the past year, Strides Pharma returned 14.8%, while the Sensex fell by 5.7%. The long-term performance is even more impressive, with a three-year return of 380.8% versus Sensex’s 15.9%, and a five-year return of 188.7% compared to the Sensex’s 46.1%. However, over the past decade, the Sensex has outperformed Strides Pharma, returning 174.2% against the stock’s 90.7%.

This relative outperformance in recent years highlights the company’s growth trajectory within the Pharmaceuticals & Biotechnology sector, despite some volatility and mixed technical signals.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Strides Pharma a Mojo Score of 56.0, reflecting a Hold rating. This is an upgrade from the previous Sell rating as of 27 Jul 2026, signalling improved confidence in the stock’s prospects. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility but also greater growth potential.

Given the mixed technical signals—mildly bullish moving averages and monthly MACD against bearish monthly RSI and KST—investors should approach the stock with measured optimism. The Hold rating suggests that while the stock is not currently a strong buy, it is no longer a sell, and may present opportunities for selective accumulation, especially if momentum indicators continue to improve.

Investment Implications and Outlook

Strides Pharma Science Ltd’s recent price momentum shift and technical indicator signals point to a stock in transition. The mildly bullish daily moving averages and monthly MACD provide a foundation for potential upward movement, but caution is warranted due to bearish signals from the monthly RSI, KST, and OBV.

Investors should monitor key technical levels, including the 52-week high of ₹1,231.45, as a breakout above this could confirm a stronger bullish trend. Conversely, a failure to sustain above current levels may lead to consolidation or retracement towards the 52-week low of ₹769.60.

In the context of the Pharmaceuticals & Biotechnology sector, Strides Pharma’s performance relative to the Sensex and its upgraded Mojo Grade suggest it remains a noteworthy contender for investors seeking exposure to small-cap growth opportunities with a moderate risk profile.

Overall, the stock’s technical landscape is characterised by a delicate balance between emerging bullish momentum and lingering bearish pressures, making it essential for investors to stay attuned to evolving market signals and volume trends.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today